2014
Single- versus Multifraction Stereotactic Body Radiation Therapy for Pancreatic Adenocarcinoma: Outcomes and Toxicity
Pollom EL, Alagappan M, von Eyben R, Kunz PL, Fisher GA, Ford JA, Poultsides GA, Visser BC, Norton JA, Kamaya A, Cox VL, Columbo LA, Koong AC, Chang DT. Single- versus Multifraction Stereotactic Body Radiation Therapy for Pancreatic Adenocarcinoma: Outcomes and Toxicity. International Journal Of Radiation Oncology • Biology • Physics 2014, 90: 918-925. PMID: 25585785, DOI: 10.1016/j.ijrobp.2014.06.066.Peer-Reviewed Original ResearchConceptsStereotactic body radiation therapyCumulative incidence rateSingle-fraction groupUnresectable pancreatic adenocarcinomaBody radiation therapyPancreatic adenocarcinomaToxicity gradeSurvival rateLocal recurrenceIncidence rateRadiation therapySingle-fraction stereotactic body radiation therapyGastrointestinal toxicity gradeMajority of patientsGastrointestinal toxicityMedian survivalWorse survivalIndependent predictorsPancreatic cancerLocal controlPatientsAdenocarcinomaRecurrenceTherapyMonths
2010
Comparison of intensity‐modulated radiotherapy and 3‐dimensional conformal radiotherapy as adjuvant therapy for gastric cancer
Minn AY, Hsu A, La T, Kunz P, Fisher GA, Ford JM, Norton JA, Visser B, Goodman KA, Koong AC, Chang DT. Comparison of intensity‐modulated radiotherapy and 3‐dimensional conformal radiotherapy as adjuvant therapy for gastric cancer. Cancer 2010, 116: 3943-3952. PMID: 20564136, DOI: 10.1002/cncr.25246.Peer-Reviewed Original ResearchConceptsIntensity-modulated radiotherapyCRT groupGastric cancerConformal radiotherapyIMRT patientsAcute gastrointestinal toxicityMedian radiation doseMedian serum creatinineGastroesophageal junction cancerOverall survival rateConcurrent chemotherapyKidney V20Liver V30Median liverRecent creatinineAdjuvant chemoradiotherapyAdjuvant therapyGastrointestinal toxicityIMRT groupLocoregional failurePostoperative chemoradiotherapyJunction cancerRenal functionSerum creatinineTreatment breaks
2009
Adjuvant chemoradiotherapy with carboplatin and a fluoropyrimidine for resectable gastric and gastroesophageal junction cancer: A retrospective review of the Stanford experience
de Bruin M, Kunz P, Sharma V, Norton J, Bastidas J, Chang D, Koong A, Koong A, Balise R, Ford J, Fisher G. Adjuvant chemoradiotherapy with carboplatin and a fluoropyrimidine for resectable gastric and gastroesophageal junction cancer: A retrospective review of the Stanford experience. Journal Of Clinical Oncology 2009, 27: e15674-e15674. DOI: 10.1200/jco.2009.27.15_suppl.e15674.Peer-Reviewed Original ResearchStanford Cancer CenterGEJ cancerAdjuvant chemoradiotherapyRetrospective reviewCycles of carboplatinPercentage of patientsGastroesophageal junction cancerGastroesophageal junction adenocarcinomaStandard of careExternal beam radiotherapyInfusional 5FUModified regimenPo bidPositive gastricResectable gastricAdjuvant treatmentCurative intentCurative resectionGastrointestinal toxicityMean followStage IBStage IIIAStage IIIBJunction cancerOverall survival